Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de Recherches Internationales Servier
With
ADIR, a Servier Group company
Age
16–69
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participant
Age ≥ 16 years
Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options
Estimated life expectancy ≥ 12 weeks (according to investigator's judgement)
Eastern Cooperative Oncology Group (ECOG) performance status \< 2
You may not be if
Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy
Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration
CD19 negative B-cell leukaemia
Burkitt cell or mixed lineage acute leukaemia
Clareo Health | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
